<DOC>
	<DOC>NCT01659970</DOC>
	<brief_summary>This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in second line in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after failure of first line platinum-based chemotherapy. Eligible patients will be followed for 12 months.</brief_summary>
	<brief_title>PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Histologically or cytologically confirmed advanced (Stage IIIB) or metastatic (Stage IV) squamous nonsmall cell lung cancer after failure of firstline platinumbased chemotherapy Patients for whom the treating physician has decided to initiate treatment with Tarceva Mixed nonsmall cell and smallcell lung carcinoma or mixed squamous cell carcinoma with predominant adenocarcinoma component Current participation in a clinical trial evaluating an anticancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>